Studying Genes in People With Heart Rhythm-Related Heart Muscle Disease
Observes genetic changes in adults with arrhythmia-induced cardiomyopathy and how they relate to outcome.
Plain-language title generated from the registry record
Registry title: Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy
Key facts
- Where
- Albacete, Ciudad Real, and Madrid, SpainSee the 4 sites
Where in Spain
- Albacete University Hospital ComplexAlbacete, SpainNot yet recruiting
- Ciudad Real General University HospitalCiudad Real, SpainTaking people
- 12 de Octubre University HospitalMadrid, SpainTaking people
- Ramón y Cajal University HospitalMadrid, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospital Universitario 12 de Octubre
- Trial code
- NCT06896266
- Record updated
- 15 September 2026
- Original description
The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are:Read full original descriptionShow less
Understanding and Characterizing the Genetics of Patients With Arrhythmia-Induced Cardiomyopathy
The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are:
I. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?
Inclusion: Presence of atrial fibrillation or atrial flutter not self-limited; Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) <50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF <50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%; Signature of informed consent; Ability to understand and accept participation in the study.
Exclusion: Presence of known factors causing systolic ventricular dysfunction:; Prior cardiomyopathy diagnosis; Severe mitral or aortic valve disease; Non-revascularizable ischemic heart disease; Context of peri-resuscitation cardiopulmonary care; Abusive alcohol consumption, defined as >80 grams of ethanol or >7 standard alcoholic beverages per day; Active treatment with chemotherapeutic agents or radiation therapy to the thorax; Known infection with Trypanosoma cruzi, Borrellia burgdorferi or other infectious agent causing cardiomyopathy; Age <18 years; Refusal of informed consent; Legal or juridical incapacity; Life expectancy less than 1 year; Impossibility of a follow-up of at least 6 months; Presence of a ventricular rate >140 beats per minute, limiting the validity of imaging measurements.